Business
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n CALGARY, AB\n \n \n ,\n \n \n Oct. 10, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the \"\n \n Debenture Units\n \n \"), on a non-brokered private placement basis, for aggregate proceeds of\n \n C$800,000\n \n (the \"\n \n Offering\n \n \"). The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of\n \n C$515,000\n \n .\n \n \n \n \n \n \n \n \n \n Each Debenture Unit consists of one 12% unsecured convertible debenture in the principal amount of\n \n C$1,000\n \n (each, a \"\n \n Convertible Debenture\n \n \") with a maturity date of\n \n October 10\n \n , 2026 (the \"\n \n Maturity Date\n \n \") and 4,762 common share purchase warrants (each, a \"\n \n Warrant\n \n \"). Each Warrant entitles the holder thereof to purchase one common share of the Company (each a \"\n \n Share\n \n \") at a price of\n \n C$0.105\n \n per Share until\n \n October 10, 2025\n \n ; provided that if, at any time prior to the expiry date of the Warrants, the 20-day volume weighted average of actual closing prices of the Shares on the Toronto Stock Exchange (the \"\n \n TSX\n \n \"), or other principal exchange on which the Shares are listed, is greater than\n \n C$0.15\n \n , the Company may accelerate the expiry date of the Warrants to the date that is 20 days following the date of the notice of such acceleration.\n \n \n The Convertible Debentures are convertible at the holder's option into Shares at any...